Posts

ADA: Metsera asset data support Pfizer’s entry point into obesity market

on

Novartis CEO Vas Narasimhan Joins Anthropic's Board

on

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

on

JPM26: Pfizer Fast-Tracks Obesity Programs in Race Against Patent Cliff

on

Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program

on

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

on

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

on

Novo Nordisk Ups the Stakes With $10B Bid for Metsera, Surpassing Pfizer's Offer

on

Delaware Court Denies Pfizer's Bid to Block Novo Nordisk-Metsera Deal

on

Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers

on

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

on

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer's Offer

on

Metsera Calls Pfizer's Threats 'Nonsense' as Rift Between Companies Widens

on

Novo Nordisk Launches Surprise Bid for Metsera, Topping Pfizer Offer; Pfizer Alleges Move May Violate Antitrust Law

on

Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends

on

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

on

Pfizer's $4.9B Metsera Deal Signals More Pharma M&A in Booming Obesity Drug Market

on

Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market

on

Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results

on

Biotech IPO Momentum: Maze and Metsera's Dual Debut Signals Renewed Market Optimism

on